BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LY-N001 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LY-N001\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07685444-8721@assetmemo.bio
DTSTAMP:20261121T005655Z
DTSTART;VALUE=DATE:20280707
DTEND;VALUE=DATE:20280708
SUMMARY:LY-N001: Phase 1 readout est. (NCT07685444)
DESCRIPTION:LY-N001\, phase 1\, Parkinson's Disease.\nStudy: A Clinical Stu
 dy to Evaluate the Safety\, Tolerability\, and Efficacy of Intracerebral I
 njection of LY-N001 Injection for the Treatment of Moderate to Advanced Pa
 rkinson's Disease With GBA1 Mutations\nEstimated primary completion: 7 Jul
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ly-n001#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07685444
URL:https://assetmemo.bio/drug/ly-n001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
